Introduction
Lung cancer has the highest incidence of malignancy and results in the highest mortality rates among all malignant diseases, with an incidence of 1.59 million deaths/year. 1 Non-small-cell lung cancer (NSCLC), the most common type of lung cancer, comprises 80%-85% of all cases. Owing to the lack of major advancements in treatment, the prognosis for NSCLC patients remains poor, with a 5-year overall survival rate of 15% of all stages. 2 In lung cancer progression, the occurrence of epithelial-mesenchymal transition (EMT) promotes invasiveness and metastasis. 3 EMT refers to the physiological process by which cells gradually lose their epithelial characteristics while acquiring mesenchymal features, which facilitates detachment from primary tumors, invasion of adjacent stroma, entrance into systemic circulation, and extravasation. [3] [4] [5] [6] [7] [8] [9] Tumor growth factorbeta 1 (TGF-β1) has been confirmed as a key factor in EMT induction. 10 This cytokine is a member of the TGF-β superfamily and plays a dual role in tumorigenesis. 11 While TGF-β1 inhibits cell proliferation in early tumor stages, initiating cell differentiation and inducing apoptosis, it can also stimulate tumor invasion and metastasis through several mechanisms during tumor progression. Further research into the molecular submit your manuscript | www.dovepress.com
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Zhang et al mechanisms of TGF-β1-induced EMT is needed to allow for the inhibition of the invasive phenotype while retaining the suppressive effects of TGF-β1 on tumor growth.
Recently, the epigenetic mechanisms involved in EMT regulation have been increasingly studied, including DNA methylation and miRNAs, which are both reported to participate in regulating EMT. Gregory et al 12 found that miR-200 family members could suppress EMT by targeting ZEB1 and ZEB2, E-cadherin transcriptional repressors. Recent, evidence suggests the existence of interactions among DNA methylation, miRNAs, and the invasion of highly aggressive bladder and breast cancers. [13] [14] [15] Therefore, we hypothesized that it may be possible to reverse EMT by epigenetic regulation, which is not currently well understood in NSCLC. Decitabine (DAC, 5-aza-2′-deoxycytidine) is a deoxyribonucleotide that is phosphorylated to 5-aza-2′-deoxycytidine monophosphate by deoxycytidine kinase, followed by further phosphorylation to 5-azadeoxycytidine triphosphate. It can be incorporated into DNA by DNA polymerase, leading to covalent capturing of the DNA methyltransferase enzyme and subsequent suppression of DNA methylation. Since DAC is in the form of deoxyribonucleoside, it can be more readily incorporated into DNA and is, therefore, considered to be more effective than azacitidine (5-azacytidine), a ribonucleoside DNA methylation inhibitor. 16 Some studies have found that DAC may affect EMT in human cancers. [17] [18] [19] To investigate this, we assessed the effect of DAC on TGF-β1-induced EMT in two NSCLC cell lines, PC9 and A549. We also determined the involvement of the miR-200/ZEB axis in this mechanism. In this study, we performed most experiments with two miR-200 family members, miR-200a and miR-200c, that together represent two subfamilies of miR-200; for the sake of simplicity, we refer to miR-200 family members collectively as miR-200 ( Figure S1 ).
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Materials and methods
Tumor cell culture and treatment
The PC9 and A549 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in monolayer in Roswell Park Memorial Institute (RPMI) 1640 (Gibco/Invitrogen, Carlsbad, CA, USA) containing 10% heat-inactivated fetal bovine serum (FBS) in a humid atmosphere at 37°C with 5% CO 2 . The cells were harvested using 0.25% trypsin at 75% confluence, and then subcultured in 75 cm 2 flasks or six-well plates. Before treated with drugs, cells were allowed to adhere to the substrate for 24 h. Two different treatments were designed and carried out after serum starvation for another 24 h: 1) 10 ng/mL human recombinant TGF-β1 (Biolegend, San Diego, CA, USA) for the TGF-β groups; 2) a combination of 10 ng/mL TGF-β1 and 10 μM DAC (Selleckchem, Houston, TX, USA) for the TGF-β+DAC groups. And the control groups were given the same amount of phosphate-buffered saline (PBS). All treatments lasted for 96 h.
animal tumor models and treatment
Five-to six-week-old female NOD/SCID mice (Beijing HFK Bioscience Co. Ltd, Beijing, People's Republic of China) were maintained in the specified pathogen-free conditions with animal food and water. The mice were injected subcutaneously into the right axillary fossa with PC9 or A549 cells (5×10 6 /100 μL). The criterion for successful model establishment is that tumors are palpable and have reached ~300-500 mm 3 at 7-10 days after inoculation. Then mice were randomly assigned into four groups (n=3 per group), and euthanized, respectively, at day 0, 3, 6 and 12. After volume measurement, tumors were immediately collected for enzyme-linked immunosorbent assay (ELISA). For assessing lymph node metastasis and survival rate, PC9 tumor-bearing mice were randomly assigned into treatment and control groups (n=5 per group for lymph node metastasis assessment, n=10 per group for survival time record). Treatments were given through intraperitoneal injection. In this research, we utilized normal saline for the control group and DAC (Selleckchem) 2.5 mg/kg every day for 10 consecutive days for the treatment group. Two weeks after termination of treatment, mice were sacrificed, four lymph nodes from bilateral neck and inguinal of every mouse were collected, and the histological analysis was performed to determine the lymph node metastasis. The survival rate of each group was recorded at the start of the treatment, and residual mice in all groups were sacrificed 7 weeks after tumor establishment. All procedures regarding the care and use of animals followed the guidelines of and were approved by the Animal Ethics Committee of Sichuan University (Approval No 2017004A).
elisa
The tumor tissue samples were prepared using liquid nitrogen grounding method and homogenized in radioimmunoprecipitation assay buffer (0.1% sodium dodecyl sulfate [SDS], 0.5% deoxycholate, 1% Triton X-100, 150 mM NaCl, and 50 mM Tris-HCl). After centrifugated at 13,300 rpm for 30 
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Decitabine reverses eMT by regulating mir-200/ZeB axis according to the manufacturer's instructions, and the colorimetric reaction was measured at 450 nm using a microplate reader (Benchmark Electronics, Angleton, TX, USA).
Microscopy images
The cultured PC9 and A549 cells were treated with TGF-β1 or TGF-β1+DAC or PBS for 96 h. Images were captured using a digital microscope (Olympus UIS2, Tokyo, Japan) at a magnification of 20× objective.
Western blotting
PC9 and A549 cells were harvested and total protein was quantified with Micro BCA Protein Assay Kit (Pierce). Total protein (20 μg) from each sample was separated by electrophoresis using 10% SDS-polyacrylamide gel electrophoresis gels, transferred onto poly(vinylidene fluoride) membranes (Merck Millipore, Billerica, MA, USA), blocked with 5% skim milk, and incubated using the corresponding primary antibodies (1:1,000), E-cadherin (Cell Signaling Technology, Danvers, MA, USA) or vimentin (Cell Signaling Technology), overnight at 4°C. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology) was used as a loading control. Blots were then incubated with the corresponding secondary antibodies (1:5,000, Cell Signaling Technology) for 1 h at room temperature. After exposed to ECL reagent (Merck Millipore) advanced luminescence, signals were developed on X-ray films (Kodak, NY, USA).
Transwell migration assays
The migration ability of PC9 cells was determined using the 24-well Transwell chambers (Corning Costar, NY, USA). After untreated or treated with TGF-β1 or TGF-β1+DAC for 96 h, the cells (1×10 5 ) were seeded in the top chambers and incubated for 24 or 48 h. The migrating cells were counted using a light microscope (Olympus UIS2; magnification, ×20, three random fields per well were analyzed by ImageJ). 21 Wound-healing assay A549 cells were seeded in six-well plates at a density of 2×10 5 cells/well in RPMI 1640 containing 10% FBS and cultured until 80%-90% confluence. The cells were then scraped with a 200-μm pipette tip to generate scratch wounds and washed twice with serum-free RPMI 1640 to remove cell debris. The experimental group cells were treated with TGF-β1 or TGF-β1+DAC at 37°C for 96 h. To record scratch wound closure, images were captured at 0-and 96-h time points in the same position using an Olympus IX71 microscope (Olympus UIS2; magnification, ×60 objective, three random fields per well were analyzed). Terminal time point image areas were normalized to the 0-h postscratch ones.
Quantitative real-time polymerase chain reaction (qrT-Pcr)
Total RNA from PC9 and A549 cells was extracted using TRIzol reagent (KeyGEN, Nanjing, People's Republic of China). RNA was reversed transcribed into cDNA using PrimeScript RT reagent Kit with gDNA Eraser (TaKaRa, Tokyo, Japan). For detecting ZEB1 and ZEB2, the cDNA template was amplified by RT-PCR using the SYBR Premix Ex TaqTM II (TaKaRa). RT-PCRs were performed in triplicate, and gene expression in each sample was normalized to GAPDH expression. The primer sequences used were listed in Table 1 
apoptosis assay
Cells (1×10 6 ) were collected, washed, and resuspended in PBS. Annexin V-FITC (5 μL/mL; KeyGEN, Nanjing, Jiangsu, People's Republic of China) and propidium iodide (KeyGEN) were added, and cells were incubated for 20 min at 4°C before analyzed by flow cytometry system (Beckman Coulter, Miami, FL, USA).
cell viability determination (XTT assay)
We
histological analysis
Bilateral neck and inguinal lymph nodes were fixed overnight in 4 wt% paraformaldehyde and embedded in paraffin. Sections of 4-μm thickness were then stained with hematoxylin and eosin and examined using an Eclipse E600 microscope (Nikon, Tokyo, Japan).
statistical analysis
Data are expressed as mean ± standard deviation. Statistical analyses were performed using the Statistical Package for the Social Sciences 24.0 (SPSS Inc., Chicago, IL, USA). Between-group statistical significance was determined using Dunnett's t-test, Student's t-test, or one-way analysis of variance with Student-Newman-Keuls multiple comparison. Significance was set at P0.05.
Results
TgF-β1 increases with tumor growth in Pc9 and a549 xenograft model
After the establishment of animal tumor models using the NSCLC cell lines PC9 and A549, transplanted tumors were resected at different time points − 0, 3, 6, and 12 days -for determination of TGF-β1 levels using ELISA. Results showed that TGF-β1 levels in tumor tissues significantly increased with tumor progression, both in PC9-and A549-transplanted tumors (Figure 1 ). This suggests that TGF-β1 plays a role in NSCLC progression. TgF-β1 induces eMT in nsclc in vitro PC9 and A549 cells were cultured in medium with or without TGF-β1 (10 ng/mL) for 96 h. Upon TGF-β1 treatment, most PC9 and A549 cells elongated to become fibroblast-like spindle-shaped cells (Figure 2A and E) . EMT-related proteins were measured by Western blot analysis. A dramatic decrease in E-cadherin and increase in vimentin were observed in both cell lines following TGF-β1 stimulation ( Figure 2B and F) . The cellular migration abilities of PC9 and A549 cells were assessed by Transwell migration and wound-healing assays, respectively. Data showed that TGF-β1 treatment significantly increased cell migration ( Figure 2C, D, and G) . These results demonstrate that NSCLC cells are induced to undergo EMT and exhibit enhanced migration abilities under TGF-β1 stimulation.
Dac inhibits TgF-β1-induced eMT in Pc9 cells in vitro
To determine whether DAC inhibits TGF-β1-induced EMT in PC9 cells, TGF-β1-stimulated PC9 cells were treated with or without DAC. Immunofluorescence revealed that DAC treatment of TGF-β1-stimulated PC9 cells induced the re-expression of epithelial markers such as E-cadherin and reduced the expression of mesenchymal markers such as vimentin ( Figure 3A) . Consistent with this finding, Transwell migration assay revealed that DAC treatment led to the suppression of cell mobility ( Figure 3B ). Western blot analysis of E-cadherin and vimentin protein expression levels confirmed the immunofluorescence results ( Figure 3C ).
Dac treatment does not affect eMT in a549 cells in vitro
While DAC inhibited TGF-β1-induced EMT in PC9 cells, a similar response was not observed in A549 cells. Experiments in A549 cells showed that DAC had no remarkable effect on the expression of E-cadherin or vimentin ( Figure 4A) . Similarly, DAC did not attenuate TGF-β1-induced enhancement of A549 cellular migration ( Figure 4B ).
epigenetic regulation of mir-200/ZeB axis is involved in TgF-β1-induced eMT
Further experiments were performed to explore the mechanism by which DAC reverses EMT in PC9 but not in A549 cells. Expression of ZEB1 and ZEB2 was determined by qRT-PCR analysis. Results indicated that TGF-β1 treatment upregulated ZEB1 and ZEB2 expression in both cell lines. DAC reduced this upregulation in PC9 cells ( Figure 5A ), but in A549 cells, ZEB1 and ZEB2 expression was not affected by DAC ( Figure 5B ). It has been suggested that ZEB1 and ZEB2 are the targets of the miR-200 family. 12 We found that expression levels of miR-200a and miR-200c were downregulated by TGF-β1 treatment and upregulated by DAC treatment in PC9 cells, suggesting a strong association between expression of miR-200/ZEB and TGF-β1/DAC treatment in PC9 cells ( Figure 5C ). In contrast, in A549 cells, in which EMT is not reversed by DAC, expression levels of miR-200a and miR-200c were not altered by TGF-β1 or DAC treatment ( Figure 5C ). We, therefore, hypothesized that DAC increases promoter methylation status of each cell line was detected by MSP. Results showed that TGF-β1 treatment induces hypermethylation of the miR-200 promoters, whereas DAC treatment induces demethylation in PC9 cells. In A549 cells, however, TGF-β1 and DAC treatments appear to have no effect on promoter methylation status ( Figure 5D differentiation, and apoptosis. 22 We performed flow cytometry and XTT assay to determine the effect of TGF-β1 on apoptosis and cell growth in PC9 and A549 cells. Flow cytometry data showed that TGF-β1 treatment promoted apoptosis in both cell lines, and this effect was enhanced when combined with DAC ( Figure 6A and B) . XTT assays revealed that the viabilities of the two cell lines were inhibited by TGF-β1. This effect was slightly enhanced when combined with DAC, but the difference was not statistically significant ( Figure 6C ). 
Dac reduces lymph node metastasis in Pc9 tumor-bearing mice
To investigate whether DAC has an antimetastasis effect in vivo, PC9 tumor-bearing nude mice were treated with DAC (2.5 mg/kg) every day for 10 days. Two weeks after termination of treatment, mice were sacrificed and the formation of lymph node metastasis was observed ( Figure 7C ). Results were consistent with our in vitro findings with a reduced lymph node metastasis rate in DAC-treated mice ( Figure 7B ). However, survival rate was not significantly different between the control and DAC groups ( Figure 7A ).
Discussion
In the present study, we investigated the effect of DAC on TGF-β1-induced EMT and the involvement of the miR-200/ ZEB axis. According to our findings, DAC treatment interfered with the miR-200/ZEB axis, thus reversing TGF-β-induced EMT in the NSCLC cell line PC9. We performed MSP and found that the miR-200 DNA promoters were hypermethylated during TGF-β1-induced EMT in PC9 cells. transfection experiments showed that TGF-β1-stimulated PC9 cell migration was significantly inhibited by the upregulation of miR-200a ( Figure S2 ). Our in vivo experiments showed that DAC inhibits lymph node metastasis of PC9 tumor-bearing mice. In addition, DAC enhances the proapoptotic effect of TGF-β1. These findings demonstrate that DAC represents a promising epigenetic therapy for NSCLC. However, we also note that DAC failed to reverse TGF-β1-induced EMT in A549 cells. thought to be responsible for gene repression. 24 Researchers have shown that TGF-β1-induced EMT in A549 cells is accompanied by histone deacetylase 6 (HDAC6)-dependent deacetylation of α-tubulin, which correlates with the expression of EMT markers. Use of an HDAC inhibitor results in the restored expression of E-cadherin. 25 In addition, histone modifications are also involved in miR-200 family-mediated regulation of EMT. Researchers have observed that the unmethylated CpG islands of the miR-200 loci are enriched in H3K4 trimethylation and H3K36 trimethylation (two marks of active transcription) and depleted in H3K27 trimethylation (a silencing transcriptional mark). 26 Additional analyses are needed to further elucidate this issue.
TGF-β1 is a multifunctional polypeptide cytokine with pleiotropic effects on tumors. TGF-β1 can inhibit cell proliferation and initiate cell differentiation in early tumor stages but it can also promote tumor invasion and metastasis by inducing EMT during tumor progression. 27, 28 Our data confirm the bifunctional mode of action of TGF-β1 in NSCLC.
The interaction between miR-200/ZEB axis in NSCLC is a characteristic manifestation of epigenetic regulation of plasticity in lung cancer cells. 29 Some researchers have suggested that TGF-β-induced NSCLC EMT is completely miR-200-dependent. 30 Shien et al 31 reported that EMT features were observed among the epidermal growth factor receptor inhibitor-resistant NSCLC cell lines. 
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Zhang et al successfully used to increase the expression of miR-200c/141 and inhibit migration and invasion induced by TGF-β in gastric cancer cell lines. 32 These results suggest a potential application of DAC in the treatment of solid tumors.
It has been reported that DAC exhibits single-agent activity through growth arrest and apoptosis induction in hematological malignancies. 33 Some researchers have reported that in melanoma and renal cell cancer cell lines, transcription of genes responsible for apoptosis was repressed by hypermethylation of CpG islands in regulatory regions, 29, [34] [35] [36] indicating that demethylation may play a role in promoting apoptosis in solid tumors. Our results demonstrated that DAC can enhance the proapoptotic effect of TGF-β (P<0.05) and inhibit NSCLC cell viability (although the difference is not statistically significant). According to these results, DAC achieved the goal of allowing for the inhibition of the invasive phenotype while retaining the suppressive effects of TGF-β1 on tumor growth.
Conclusion
We found that the DNA methyltransferase inhibitor DAC reverses TGF-β1-induced EMT by reversing the aberrant methylation of miR-200 promoters and regulating the miR-200/ZEB axis in NSCLC. To date, there is no clear clinical evidence that single-drug treatment with DAC prolongs the survival of patients with solid tumors. In our experiment, the survival rate of PC9 tumor-bearing mice treated with DAC was not significantly different from that of control mice. However, lymph node metastasis was lower in the treatment group than in the control group, which may reflect DAC-induced inhibition of EMT. Our findings suggest that a better understanding of the effect of epigenetic agents on EMT may improve treatment for NSCLC.
